Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug or are already an established presence in the market. Alongside R&D, CI is crucial to businesses that want to maximize the value of their science.
In this white paper, Ben Doran and Jeanne Penn draw on their experiences in the pharmaceutical field to explain how insights can be targeted to maximize the return on investment. This is critical in the biotech business because focusing on meaningful differentiation sets the foundation for value creation.
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in CI and to highlight the strategic imperatives and actionable recommendations to face these challenges head-on. We developed a white paper to summarize the research and provide our insights and expertise.
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market and how biopharmaceutical companies can optimize the performance of their brands. We discuss the impact and implications of these industry trends on brand teams and the strategies they can leverage to maximize their products’ potential. The following key trends have emerged: